HR Execs on the Move

Immunomic Therapuetics

www.immunomix.com

 
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company headquartered in Hershey, PA with lab facilities in Rockville, MD. ITI is developing next generation vaccines based on the patented Lysosomal Associated Membrane Protein, or LAMP, Technology. Our LAMP-Vax™ vaccine platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. LAMP emerged from $20 million of NIH-funded research conducted by distinguished scientist Dr. Tom August at the Johns Hopkins University School of Medicine. ITI has the exclusive worldwide license to the ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.immunomix.com
  • 1214 Research Blvd Suite 2016
    Hershey, PA USA 17036
  • Phone: 717.327.1919

Executives

Name Title Contact Details

Similar Companies

IQuum

IQuum is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CordenPharma

CordenPharma is a Boulder, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Angion

Angion Biomedica Corp. is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion`s lead product candidate, ANG-3777, is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF) to activate the HGF/c-Met pathway, which has a central role in tissue repair and organ recovery. Enrollment is ongoing in a placebo-controlled Phase 3 registration trial examining the efficacy of ANG-3777 in reducing the severity of transplant-associated acute kidney injury, also known as delayed graft function, in patients at risk for kidney dysfunction. ANG-3777 is also in a Phase 2 clinical trial for the treatment of acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass. Angion is also developing ANG-3070, an orally-bioavailable small molecule, as a potential treatment for a variety of chronic fibrotic diseases sharing similar underlying disease-driving pathways identified and targeted using a precision-medicine approach.

VivoQuest

VivoQuest, Inc. is a Valley Cottage, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

New Jersey Precision Technology

New Jersey Precision Technology is a Mountainside, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.